76
Participants
Start Date
January 5, 2021
Primary Completion Date
March 31, 2022
Study Completion Date
August 31, 2022
Trivalent Influenza Vaccine
We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
AMC Hospital, Bandung
Collaborators (1)
Biofarma
INDUSTRY
Universiti Sains Malaysia
OTHER
Universitas Padjadjaran
OTHER